Science + Serendipity

About 10 years ago, serendipity made a big wave on the Manistee River by the company founders. A concept for a new pharmaceutical treatment was formed with just the right type of people fishing together; three physicians and one scientist / serial entrepreneur. Medically observant, inquisitive, creative, and driven by their entrepreneurial spirit, the founders sought to explore the initial concept. However, while persistently pursuing the idea, they unexpectedly discovered a promising treatment for migraine.

Hence, the company Manistee Therapeutics was founded on serendipity and dedicated scientific observations and study. Scientific advancements, including drug discovery, are usually the product of years of dedicated research. At Manistee, we invite you to be part of our scientific mission to help migraine patients. Your engagement in our clinical trials is essential to development of a novel treatment option for migraine management .

Founders

Robert L. Bratzler

Bob has helped build, lead and grow 4 healthcare companies from inception to successful IPO’s on NASDAQ (Sepraor, Coley Pharmaceuticals, ChiRex, and Selecta Biosciences). He was co-founder of Sepracor which was acquired by Sumitomo Pharma (previously Sunovion Pharmaceuticals). He is an experienced biotech executive with numerous advisory roles to healthcare start-up companies. He is trained in chemical engineering receiving his PhD from MIT.
Bradford-J.-Shingleton

Brad was a member of the Ophthalmic Consultants of Boston (OCB) and associate clinical professor at Harvard Medical School (retired). He is a past President of the American Society of Cataract and Refractive Surgery, and recipient of Honor Award, Senior Achievement Award, and Lifetime Member from the American Academy of Ophthalmology. He is the author of over 100 scientific publications including senior editor of the textbook Eye Trauma and Handbook of Eye Emergencies. He was past team Ophthalmologist for the Boston Bruins, Boston Red Sox, New England Patriots and New England Revolution.

Martin Wand

Martin previously served as Clinical Professor of Ophthalmology at University of Connecticut Medical School (Emeritus). He is past chair of American Board of Ophthalmology as well as prior chair of the council and trustee of the 27,000-member American Academy of Ophthalmology. He is the recipient of Life Achievement Honor Award from American Academy of Ophthalmology in 2010. His extensive academic contributions include 63 articles in peer-reviewed medical journals 25 chapters in medical text books, and 162 medical talks & named lectures. Martin is a graduate of Yale undergrad and medical school, and Harvard’s Mass Eye Infirmary residency and fellowship. He is also an avid fly fisherman & wine aficionado.

Frederick C. Ryckman

Fred previously served as Professor of Surgery at University of Cincinnati Medical School (Emeritus). He practiced for 35 years as a Pediatric Surgeon / Transplant Surgeon along with non-clinical leadership roles to include Sr. Vice President for Medical Operations as well as interim Chief Operating Officer at Cincinnati Children’s Hospital. He has authored over 135 medical publications and 45 book chapters. He has consulted globally on his specialty and continues to teach Hospital Quality and Safety with the Institute for Healthcare Improvement.

MANISTEE THERAPEUTICS

MIGRAINE TREATMENT CLINICAL TRIALS

Innovative new study on pain relief

Migraine is a global problem affecting greater than 10% of the population

(859 million globally)

More than 44 million individuals are affected in the USA.